BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 01, 2011
 |  BioCentury  |  Finance

Passage to India

BB Biotech makes first investments in India: Glenmark, Lupin, Strides Arcolab

Lured by strong market growth prospects and diversified risk portfolios, BB Biotech AG pulled the trigger on its first investments in Indian biotechs last quarter. The three new portfolio companies - Glenmark Pharmaceuticals Ltd., Lupin Ltd. and Strides Arcolab Ltd. - each offer a different ratio of innovator to generic products.

In its 2Q report to shareholders last week, BB Biotech expressed confidence that the healthcare sector would perform well this half, and said it plans to continue reallocating assets from large cap to small and mid-cap biotechs.

In addition to shifting towards smaller names, the biotech investment company unveiled its first move into emerging markets. This new strategic direction has been a couple of years in the making, according to BB Biotech's Stefan Muller.

"We started...

Read the full 631 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >